MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
3.050
+0.080
+2.69%
After Hours: 3.050 0 0.00% 16:01 12/01 EST
OPEN
2.960
PREV CLOSE
2.970
HIGH
3.140
LOW
2.960
VOLUME
408.87K
TURNOVER
0
52 WEEK HIGH
7.39
52 WEEK LOW
2.770
MARKET CAP
234.88M
P/E (TTM)
-3.9487
1D
5D
1M
3M
1Y
5Y
These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts
Market forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts...
Simply Wall St. · 11/13 12:10
Ocular Therapeutix And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 11/10 10:41
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Benzinga · 11/09 10:08
Ocular Therapeutix hits 52-week low after slashing revenue guidance
Seekingalpha · 11/08 18:13
Ocular falls 12% as eye therapy Dextenza Q3 sales decline, cuts FY22 outlook
Seekingalpha · 11/08 17:56
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 11/08 17:51
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
Benzinga · 11/08 16:30
Ocular Therapeutix Q3 Loss Widens, Revenue Drops; Shares Fall Sharply Tuesday
Ocular Therapeutix Q3 Loss Widens, Revenue Drops; Shares Fall Sharply Tuesday
MT Newswires · 11/08 14:19
More
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocularitching associated with allergic conjunctivitis. Its earlier stage development assets include axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet AMD and other retinal diseases. Its travoprost intracameral implant (OTX-TIC) is under Phase II clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. It has also completed Phase II clinical trials for cyclosporine intracanalicular insert (OTX-CSI) for the chronic treatment of dry eye disease and dexamethasone intracanalicular insert (OTX-DED) for the short-term treatment of the signs and symptoms of dry eye disease.

Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.